Last reviewed · How we verify

Intraarterial application of Octreotide

St. Josef Hospital Bochum · Phase 1 active Small molecule Quality 0/100

Intraarterial application of Octreotide is a Small molecule drug developed by St. Josef Hospital Bochum. It is currently in Phase 1 development. Also known as: Sandostatin (Novartis Pharma, Switzerland), Bendatreotid, Octreo, Siroctid.

At a glance

Generic nameIntraarterial application of Octreotide
Also known asSandostatin (Novartis Pharma, Switzerland), Bendatreotid, Octreo, Siroctid, Octreotid
SponsorSt. Josef Hospital Bochum
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Intraarterial application of Octreotide

What is Intraarterial application of Octreotide?

Intraarterial application of Octreotide is a Small molecule drug developed by St. Josef Hospital Bochum.

Who makes Intraarterial application of Octreotide?

Intraarterial application of Octreotide is developed by St. Josef Hospital Bochum (see full St. Josef Hospital Bochum pipeline at /company/st-josef-hospital-bochum).

Is Intraarterial application of Octreotide also known as anything else?

Intraarterial application of Octreotide is also known as Sandostatin (Novartis Pharma, Switzerland), Bendatreotid, Octreo, Siroctid, Octreotid.

What development phase is Intraarterial application of Octreotide in?

Intraarterial application of Octreotide is in Phase 1.

Related